2022
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma
Avery J, Chandhok N, Rainey C, Torres R, Huntington S, Isufi I, Seropian S, Xu ML, Foss F. Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2022, 22: 680-689. PMID: 35568635, DOI: 10.1016/j.clml.2022.04.019.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaBone marrow involvementBlood involvementFlow cytometryMarrow involvementNodal subtypesAggressive peripheral T-cell lymphomaNodal T-cell lymphomasNegative flow cytometryPeripheral blood involvementPositive flow cytometryMalignant T cellsMalignant tumor cellsMedian PFSTime ofdiagnosisOverall survivalLymph nodesPoor outcomeDisease stagePeripheral bloodT cellsPrognostic measuresRare subgroupLymphoma
2020
Cutaneous Involvement in Plasma Cell Myeloma
Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.Peer-Reviewed Original ResearchConceptsPlasma cell myelomaCutaneous involvementSquamous cell carcinomaAmyloid depositionCell carcinomaCell myelomaCases of PCMBone marrow involvementCyclin D1 immunoreactivityDisease-related deathLight chain restrictionCCND1 gene rearrangementMarrow involvementSkin involvementClinicopathologic featuresCytomorphologic spectrumCutaneous lesionsPoor outcomeCommon immunophenotypeChain restrictionClinical dataCytogenetic findingsOlder individualsGene rearrangementsMyeloma